Q2 earnings set for July 31 with EPS up 9.8% YoY. Revenue to grow 3.9%. Discover key updates on its portfolio, guidance & M&A ...

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

A look at the shareholders of AbbVie Inc. (NYSE:ABBV) can tell us which group is most powerful. We can see that institutions ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at $185.62 as of June 30th.

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

This was the stock's third consecutive day of losses.

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

Go Higher. AbbVie’s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It’s gone up by 100 percent since then. By Danny Hakim ...